Your session is about to expire
← Back to Search
Triple Drug Combo for Colorectal Cancer
Study Summary
This trial will test a new combination of cancer drugs to see if it is effective in treating subjects with metastatic colorectal cancer who have not responded to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently receiving IV treatment for an infection.I am 18 years old or older.I have HIV, HBV, or HCV, or I had HBV or HCV but it's now cleared.I haven't had major surgery or intense cancer treatment in the last 3 weeks.I am a male and will use effective birth control during and for 7 months after the study.My cancer does not have mutations in specific genes (KRAS, NRAS, BRAF).My kidney function tests are within the required range.I am not pregnant and agree to use birth control or abstain from sex during and 5 months after treatment.My colorectal cancer is advanced and cannot be removed by surgery.I haven't needed strong medication for an autoimmune disease in the last 3 months.I've had 1-2 treatments before, or my cancer returned within 6 months after specific chemotherapy.My recent liver tests meet the study's requirements.I can provide tumor tissue samples or agree to a biopsy for the study.I am unable or unwilling to follow the study's requirements.I have brain metastasis that hasn't been treated or was treated within the last 3 months.I haven't had cancer treatment in the last 21 days and have recovered from past treatments.I have a lung condition not caused by an infection.I have another cancer, but it's either inactive or a minor type that doesn't require treatment.My cancer is microsatellite stable or has normal mismatch repair.I have not had an organ transplant, immune system issues, or taken immune-weakening medicines in the last week.I have been treated with drugs that target the immune system.I am fully active or restricted in physically strenuous activity but can do light work.I have been treated with drugs targeting EGFR like cetuximab or panitumumab.
- Group 1: Open-label, single arm, Phase II
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What therapeutic purposes is panitumumab generally employed for?
"Panitumumab is used to treat diseases that have not responded to anti-angiogenic therapies, such as malignant neoplasms and squamous cell carcinoma. It may also be useful for treating unresectable melanomas."
Are there still opportunities for participants to join this experiment?
"This medical trial is no longer searching for participants. Initially posted on March 9, 2018 and last updated November 11, 2022; alternative trials are available with 243 actively recruiting patients suffering from colon cancer and 796 wherein Panitumumab is being trialled."
Are there any Canadian sites participating in the trial?
"At present, this medical trial is accepting participants from 5 clinical sites. Indianapolis, Tampa and Seattle are some of the cities hosting these centres while two other locations remain undisclosed. Prospective patients should look for a site close to them in order to lessen travelling requirements."
Has Panitumumab gained sanction from the FDA?
"Despite the lack of evidence for its efficacy, panitumumab is believed to have a certain degree of safety due to being in clinical trials and thus was given a rating of 2."
Is this trial open to geriatric participants?
"This medical trial is searching for participants who are of legal age or older, but not exceeding 120 years."
What is the aggregate number of individuals who have enrolled in this research?
"This research project is no longer recruiting participants, having been posted on March 9th 2018 and last updated November 11th 2022. If looking for alternatives studies, there are presently 243 trials concerning colorectal cancer enrolling people and 796 that use Panitumumab as an intervention actively admitting patients."
Have any other research projects been conducted with Panitumumab?
"Currently, 89 Phase 3 Panitumumab trials are taking place out of the 796 clinical studies that have been set up for this drug. While mostly based in Pittsburgh, Pennsylvania, 43228 different sites offer access to these experiments."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger